| With more than 800 specialty medications in the pipeline, there is no doubt the impact of these medications will be felt in the years ahead as they become an increasing share of plans’ pharmacy expenditures. According to IMS Health, in 2006, U.S. sales of biotech products alone -- a subset of specialty medications -- reached $40 billion. With a projected annual growth rate of 20 percent in the next few years, sales of specialty medications could top $100 billion by 2010 and represent more than 25 percent of total drug spend. |